Pre-Market BUZZERS: RIM and Nike PLUMMET, Arena RALLY Renewed

Research in Motion (NASDAQ:RIMM) shares are plunging 17 percent ahead of the opening bell Friday. The BlackBerry maker reported a first-quarter loss excluding items of 37 center per share, down from a profit of $1.33 per share a year earlier. Analysts were only expecting a loss of about 3 cents per share. Furthermore, RIM delayed its new release of the BlackBerry lineup and announced plans to cut 5,000 jobs.

Nike Inc. (NYSE:NKE) shares took a surprising fall of nearly 12 percent in pre-market trading. The company announced that net income in the fourth-quarter declined to $549 million ($1.17 per share), compared to $594 million ($1.23 per share) a year earlier. However, it was the fifth quarter in a row that Nike saw shrinking gross margins, as they fell 1.5 percentage points from the year-earlier quarter to 42.8 percent. Over that time, margins have contracted on average 2.4 percentage points per quarter on a year-over-year basis. Shares of competitor Under Armour Inc. (NYSE:UA) also declined 3.77 percent.

Don’t Miss: BIG BANKS Take Investors on a Wild Ride

TIBCO Software Inc. (NASDAQ:TIBX) shares dropped 2.87 percent in extended trading hours, despite reporting better-than-expected second-quarter results. This morning, shares are actually ticking higher ahead of Friday’s open. Net income came in at $26.6 million (16 cents per share), compared to $21 million (12 cents per share) a year earlier. “We delivered another quarter of continued growth, with total revenue and license revenue up by 20 percent and 17 percent respectively, after adjusting for currency movements,” said Vivek Ranadiv, TIBCO’s chairman and CEO. “A growing list of customers across industries and geographies are harnessing big data and becoming event-driven through the use of our infrastructure software platform – whether for new demand generation, improved loyalty program returns, increased operational efficiencies, or superior risk management. In up markets and down, these remain priority initiatives that continue to create opportunities for TIBCO.”

Investors and traders continued to book profits in Arena Pharmaceuticals Inc. (NASDAQ:ARNA) Thursday. The company closed 10.18 percent lower on Thursday. However, shares are bidding higher 1.76 percent before the opening bell Friday. The company won approval by the Food and Drug Administration on Wednesday for its weight-loss drug lorcaserin. It is the first obesity medication cleared for sale in the United States in 13 years.

Investor Insight: GOLD: Safe Haven or Risky Investment?